Same Label, Different Filling Line: Five Questions on Aseptic Fill-Finish
Two CDMOs can both list “aseptic fill-finish” and offer very different manufacturing setups. These five questions help sponsors see what sits behind the label.
The industrial side of pharmaceutical outsourcing — capacity, chemistry, and the decisions behind them. Briefs from our analysis series, product updates, and featured CDMO partners.
Two CDMOs can both list “aseptic fill-finish” and offer very different manufacturing setups. These five questions help sponsors see what sits behind the label.
Cyclisation and purification decisions made at milligram scale set the cost of goods at kilogram scale. By the time the candidate is chosen, the route is hard to change.
22 signed deals in eight weeks, worth about US$24 billion in total potential value. Most of that depends on future milestones, and at least 8 of the 10 largest deals cover medicines not yet tested in patients.
Most sponsors choose a CRO on proposal price, brand recognition and a bid-defense meeting. Trials slip on what the proposal does not show: which sites activate, which team stays, how change orders are priced and who owns the data. A defensible shortlist is built on evidence a CRO can produce from its own records.
Peptide-based oncology programs use comparatively little API, but their manufacturing needs are exacting: small-scale GMP availability, specification control, analytical capability, inspection readiness, and a supply chain aligned to the patient.
Most peptide CDMO selection frameworks were written when capacity was available. They ask reasonable questions at the wrong level of specificity — and where qualified commercial capacity is scarce, that imprecision costs a place in the queue. Six recurring failure modes, and the evidence that settles each one.
Solid-phase peptide synthesis consumes around 13,000 kg of material for every kg of API — forty to eighty times a small molecule. As GLP-1-class demand pushes volumes the industry has never operated at, solvent supply, recovery, and disposal are becoming the binding constraint.
We tracked more than twenty peptide facility announcements from 2024 to 2026. Only a handful add commercial-scale API capacity — and in 2026, consolidation quietly shrank the field rather than widening it.
Two Phase 3 readouts have reset the ceiling for what peptide therapeutics can do. The more interesting story is everything the efficacy headline leaves out.